Meta analysis of Immune checkpoint inhibitor induced cardiotoxicity
Tanja Obradovic shared on LinkedIn:
“Important article reporting outstanding work of systematic review and meta analysis of immune checkpoint inhibitor (ICI) induced cardiotoxicity is just out. Authors concluded that although ICI-induced myocarditis is relatively rare (approximately 1% incidence) it is associated with substantial mortality rate of 38%. This suggest that it is highly important for clinicians to be knowledgeable about recognition of ICI-induced myocarditis symptoms and management.
Considering large number of cancer patients worldwide receiving ICIs administered for at least 40 different malignancy indications kudos to authors for contributing to deeper understanding of toxicities and highlighting improvements in appropriate treatments as of great importance for improved cancer patient care.”
‘Immune Checkpoint Inhibitor–Induced Cardiotoxicity‘
Authors:
Source: Tanja Obradovic/LinkedIn
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.